Clinical Trial Update: Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating subcutaneous dupilumab for asthma and wheeze in children aged 2 to under 6 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Dupilumab (Dupixent) (Dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Wheezing, Asthma | Phase 3 | Status: RECRUITING